Targeted Drug-Delivery PROTEOTHERA, INC. To Present at BioTech Showcase ™ Monday, Jan. 11 at 11:30 am PT

Share Article

ProteoThera, Inc., an early stage biotech platform company that is developing therapies for the local delivery of validated and FDA approved drugs, peptides, and small molecules to treat autoinflammatory diseases and tissue regeneration, today announced that its Chief Executive Officer, Patrick O’Donnell, will present the Company’s novel targeted drug-delivery platform technology, internal product development strategy, and research collaboration opportunities at the 8th annual BioTech Showcase conference on Monday, January 11. Dr. Parth Patwari, ProteoThera’s Chief Science Officer, will also be in attendance and available for investment community and strategic research collaboration meetings.

January 5, 2016 (PRWEB) January 08, 2016 -- ProteoThera, Inc., an early stage biotech platform company that is developing therapies for the local delivery of validated and FDA approved drugs, peptides, and small molecules to treat autoinflammatory diseases and tissue regeneration, today announced that its Chief Executive Officer, Patrick O’Donnell, will present the Company’s novel targeted drug-delivery platform technology, internal product development strategy, and research collaboration opportunities at the 8th annual BioTech Showcase conference on Monday, January 11(th) at 11:30 Pacific Time. Dr. Parth Patwari, ProteoThera’s Chief Science Officer, will also be in attendance and available for investment community and strategic research collaboration meetings.

About ProteoThera, Inc.
ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology. The Company's transformative platform technology, a proprietary tissue matrix-binding (MB) peptide technology, is being developed to improve clinical efficacy and safety of FDA approved and validated therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration.

The MB technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally delivered proteins, peptides, and small molecules. ProteoThera’s focus on previously validated or approved therapies greatly de-risks the clinical, regulatory, and commercial pathways. By keeping therapies where they are needed to enable therapeutic effect, the MB platform may also improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure.

ProteoThera’s first development priority is the use of PRT-1000 (MB - Interleukin 1 Receptor Antagonist or MB-IL1RA) for treatment of acute gout pain. IL1RA is a potent cytokine inhibitor, already FDA approved for systemic administration in rheumatoid arthritis. Gout is a large and growing market with total gout drug sales projected to double to more than $2 Billion by 2018 in the US and Europe.

About BioTech ShowcaseTM
BioTech Showcase is an investor and networking conference providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and industry executives in one place during the course of one of the largest annual gatherings of healthcare investors. Now in its eight year, BioTech Showcase 2016 is expected to attract upwards of 2,100 attendees.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patrick ODonnell
Visit website

Media